1. Home
  2. ALLO vs PCYO Comparison

ALLO vs PCYO Comparison

Compare ALLO & PCYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • PCYO
  • Stock Information
  • Founded
  • ALLO 2017
  • PCYO 1976
  • Country
  • ALLO United States
  • PCYO United States
  • Employees
  • ALLO N/A
  • PCYO N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • PCYO Water Supply
  • Sector
  • ALLO Health Care
  • PCYO Utilities
  • Exchange
  • ALLO Nasdaq
  • PCYO Nasdaq
  • Market Cap
  • ALLO 252.9M
  • PCYO 267.7M
  • IPO Year
  • ALLO 2018
  • PCYO N/A
  • Fundamental
  • Price
  • ALLO $1.43
  • PCYO $11.22
  • Analyst Decision
  • ALLO Buy
  • PCYO
  • Analyst Count
  • ALLO 12
  • PCYO 0
  • Target Price
  • ALLO $8.80
  • PCYO N/A
  • AVG Volume (30 Days)
  • ALLO 2.9M
  • PCYO 40.0K
  • Earning Date
  • ALLO 11-06-2025
  • PCYO 11-12-2025
  • Dividend Yield
  • ALLO N/A
  • PCYO N/A
  • EPS Growth
  • ALLO N/A
  • PCYO 123.89
  • EPS
  • ALLO N/A
  • PCYO 0.56
  • Revenue
  • ALLO N/A
  • PCYO $27,447,000.00
  • Revenue This Year
  • ALLO N/A
  • PCYO N/A
  • Revenue Next Year
  • ALLO $100.00
  • PCYO N/A
  • P/E Ratio
  • ALLO N/A
  • PCYO $19.84
  • Revenue Growth
  • ALLO N/A
  • PCYO 40.36
  • 52 Week Low
  • ALLO $0.86
  • PCYO $9.65
  • 52 Week High
  • ALLO $3.78
  • PCYO $14.63
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 64.79
  • PCYO 54.73
  • Support Level
  • ALLO $1.29
  • PCYO $11.03
  • Resistance Level
  • ALLO $1.43
  • PCYO $11.33
  • Average True Range (ATR)
  • ALLO 0.07
  • PCYO 0.26
  • MACD
  • ALLO 0.02
  • PCYO -0.04
  • Stochastic Oscillator
  • ALLO 78.17
  • PCYO 24.05

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

Share on Social Networks: